Mosaic (genetics)

Dr. Gary Nakhuda to Present Insights on Mosaic Embryo Transfer at CFAS Annual Meeting 2023

Retrieved on: 
Giovedì, Settembre 21, 2023
Olive, Transfer, Reproductive medicine, Pregnancy, PGT, Patient, NGS, DNA sequencing, Mosaic, Research, Multimedia, Cell, IVF, Science, Genetic counseling, Fertility, Genetic testing, Knowledge, Literature, Mosaic (genetics), Conference, NIPT, Birmingham Women's Fertility Centre, Medical device, Silviculture, Birth control, Aneuploidy

VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.
  • Furthermore, Dr. Nakhuda will discuss insights from Olive's extensive data and experience with PGT-A, adding an invaluable layer of real-world context to the discussion.
  • Dr. Gary Nakhuda explains, "Embryonic mosaicism refers to the co-existence of cells with normal chromosome complements and others with apparent abnormalities.
  • Dr. Gary Nakhuda's presentation promises to be a significant contribution to the CFAS 2023 event, offering valuable insights that could shape the future of reproductive medicine.

NIH Awards $14.4 Million to NDRI to Collaborate on the Somatic Mosaicism across Human Tissues (SMaHT) Network

Retrieved on: 
Mercoledì, Maggio 17, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Other Science, Science, Education, Tissue, National Disease Research Interchange, Genetic variation, DNA, Pediatrics, Senior, Ageing, Mosaic, ELSI, U24, Cell, Fertilisation, Bangladesh Technical Education Board, Associate, Maryland School, University of Maryland School of Medicine, History of the University of Maryland, College Park, Organization, Acquisition, Brain, Map, NDRI, TPC, Mosaic (genetics), Knowledge, Hospital, Johns Hopkins, National Institutes of Health Common Fund, NIH, Disease, Pharmaceutical industry, Management

The five-year award is part of a new NIH Common Fund program called the Somatic Mosaicism across Human Tissues (SMaHT) Network.

Key Points: 
  • The five-year award is part of a new NIH Common Fund program called the Somatic Mosaicism across Human Tissues (SMaHT) Network.
  • The initiative will provide the first comprehensive public resource for analyzing genetic variation due to somatic mosaicism in human tissues from all developmental layers in the human body.
  • “NDRI is thrilled to serve as the Tissue Procurement Center for the SMaHT Network,” says Bill Leinweber, President and CEO of NDRI.
  • “Human tissue is the fundamental resource for achieving the objectives of the SMaHT Network.

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Lunedì, Dicembre 13, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, CIEMAT, Lists of diseases, HSCT, NASDAQ, Survival, Pyruvate kinase deficiency, Anemia, Risk, MMC, California Institute for Regenerative Medicine, Squamous cell carcinoma, Patient, CIRM, Adult, Blood, FDA, Pneumonia, DNA repair, Diagnosis, DEB, PKD, Splenectomy, FANCA, AAV, Head, Mutation, Regenerative medicine, Pyruvate kinase, Fanconi anemia, Safety, Quality of life, Grant, Birth, ASH, Union, ITGB2, Osteopetrosis, Heart failure, Investor, COVID-19, IMO, SEC, Research, Marketing, DNA, Prevalence, Sepsis, Centro, Danon disease, FA, Șaeș, Death, Life, Private Securities Litigation Reform Act, Genetic disorder, CD18, Mosaic (genetics), Hematopoietic stem cell transplantation, Bone marrow failure, Mortality, LVV, PKLR, Infection, Pharmaceutical industry, Vaccine, Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, Rocket Pharmaceuticals, Inc., FANCONI ANEMIA, LEUKOCYTE ADHESION DEFICIENCY-I, PYRUVATE KINASE DEFICIENCY, ROCKET PHARMACEUTICALS, INC.

RP-L301 continues to be well tolerated, with no drug product related SAEs or infusion-related complications observed through 12-months post-treatment.

Key Points: 
  • RP-L301 continues to be well tolerated, with no drug product related SAEs or infusion-related complications observed through 12-months post-treatment.
  • At approximately 12-months post-treatment the patient had normalized hemoglobin levels of 14.8 g/dL, compared to a pre-treatment baseline of ~7.0 g/dL.
  • Rocket will host an in-person Investor and Analyst Event that will simultaneously be webcast tomorrow, Dec. 14, at 7:30 a.m.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition.

Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Giovedì, Novembre 4, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Safety, Medication, Head, Bone marrow failure, Definitive, Hematopoietic stem cell transplantation, FA, ASH, Life, Marketing, Danon disease, COVID-19, Lists of diseases, Birth, Prevalence, Doctor of Philosophy, Pyruvate kinase, Death, Lifting, Diagnosis, HSCT, Stanford University School of Medicine, Survival, CD18, European Union, Squamous cell carcinoma, Private Securities Litigation Reform Act, DNA repair, Mosaic (genetics), Risk, LVV, Stanford University, FANCA, Pneumonia, MMC, CA, Fanconi anemia, Mutation, SEC, IMO, Center, Splenectomy, CIEMAT, Union, Sepsis, Genetic disorder, ITGB2, DEB, Heart failure, Patient, Society, AAV, Adult, DNA, PKLR, Abstract (summary), Infection, Pyruvate kinase deficiency, NASDAQ, Centro, Mortality, PKD, Osteopetrosis, Pharmaceutical industry, Healthcare, Vaccine, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, Fanconi Anemia, Rocket Pharmaceuticals, Inc., PYRUVATE KINASE DEFICIENCY, LEUKOCYTE ADHESION DEFICIENCY-I, FANCONI ANEMIA, ROCKET PHARMACEUTICALS, INC.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces upcoming data presentations at the 63rd American Society of Hematology (ASH) Annual Meeting taking place virtually and in Atlanta, Georgia from December 11-14, 2021.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces upcoming data presentations at the 63rd American Society of Hematology (ASH) Annual Meeting taking place virtually and in Atlanta, Georgia from December 11-14, 2021.
  • Presentations will include updated clinical data from three of Rockets lentiviral vector (LVV)-based gene therapy programs.
  • Mutations in the PKLR gene result in increased red cell destruction and the disorder ranges from mild to life-threatening anemia.
  • PKD has an estimated prevalence of 3,000 to 8,000 patients in the United States and the European Union.

Personalis Announces Issuance of US Patents Related to the Exome-Wide NeXT Liquid Biopsy Platform

Retrieved on: 
Martedì, Ottobre 26, 2021
Oncology, Professional Services, Health, Legal, Genetics, Pharmaceutical, Biotechnology, Red blood cell, Method, Efficiency, GxP, Technology, Genetic, Cancer, Genome, Disease, USPTO, System, Mosaic, Genomics, Drug development, Nucleic acid, PSNL, Twitter, Patient, Liquid biopsy, U.S. Securities and Exchange Commission, CHIP, Leadership, VP, Risk, Patent, Biomarker, COVID-19, Genetic testing, Mosaic (genetics), Growth, Intellectual property, Organic acid, Solution, Nasdaq, Immune system, VA, Anatomical terms of location, Plasma, Vaccine, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy .

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy .
  • The issuance of these patents further strengthens the companys significant intellectual property estate in the field of advanced cancer detection and analysis.
  • To date, Personalis has been granted 18 US and foreign patents relating to advanced genomic sequencing and analysis solutions.
  • For over ten years, Personalis has been focused on innovation, said John West, Personalis Chief Executive Officer.